{"id":79752,"date":"2026-04-19T12:05:09","date_gmt":"2026-04-19T12:05:09","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/fedora-pharmaceuticals-presentations-at-2026-escmid-highlight-safety-and-potent-bactericidal-activity-of-fpi-2119\/"},"modified":"2026-04-19T12:05:09","modified_gmt":"2026-04-19T12:05:09","slug":"fedora-pharmaceuticals-presentations-at-2026-escmid-highlight-safety-and-potent-bactericidal-activity-of-fpi-2119","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/fedora-pharmaceuticals-presentations-at-2026-escmid-highlight-safety-and-potent-bactericidal-activity-of-fpi-2119\/","title":{"rendered":"Fedora Pharmaceuticals Presentations at 2026 ESCMID Highlight Safety and Potent Bactericidal Activity of FPI-2119"},"content":{"rendered":"
\n

Potent antibacterial activity against Gram-negative community and hospital-acquired infections highlighted across eight posters and two presentationS<\/em><\/p>\n

EDMONTON, Alberta , April 19, 2026 (GLOBE NEWSWIRE) — Fedora Pharmaceuticals, Inc.<\/a>, a leader in the development of drugs to treat antibiotic-resistant infections, is presenting a full suite of preclinical findings from the company\u2019s lead candidate, FPI-2119 at the European Society of Clinical Microbiology and Infectious Diseases Congress (ESCMID) in Munich, Germany. Presentations at ESCMID are authored by Fedora as well as collaborators at St. Jude Children\u2019s Research Hospital, JMI Laboratories (Part of Element), Indiana University, and Pharmacology Discovery Services (a Eurofins Discovery Partner Lab).<\/p>\n

ESCMID presentations will highlight the candidate\u2019s activity against some of the most difficult-to-treat Gram-negative infections, including respiratory tract infections, sexually transmitted infections, and high-mortality nosocomial infections. Many of these pathogens are in the high-priority category in the World Health Organization (WHO) Bacterial Priority Pathogens List (BPPL) due to the public health challenges they present and the limited treatment options available.<\/p>\n

\u201cFor decades, the medical community has relied on antibiotics to ensure the effective treatment of both hospitalized patients and those with community-acquired infections such as urinary tract infections (UTIs),\u201d explained Karen Bush, Ph.D.<\/a>, Indiana University professor emerita and member of the Fedora scientific advisory board. \u201cResearch into new antibacterial agents is very limited in spite of the fact that pathogens continue to evolve new resistance mechanisms. Every year increasing treatment failures occur to previously reliable antibacterial agents. This puts hospital patients and the greater community at serious risk of succumbing to infections that were once easily treatable. The data being presented at ESCMID show that FPI-2119 has the potential to become a valuable tool to fight today\u2019s infectious diseases.\u201d<\/p>\n

Fedora\u2019s poster presentations at ESCMID highlight the following findings from preclinical studies of FPI-2119:<\/p>\n